Showing 1 - 8 results of 8 for search 'Hiroki HASEGAWA', query time: 0.06s Refine Results
  1. 1
    Impurity ion transport by filamentary plasma structures

    Impurity ion transport by filamentary plasma structures by Hiroki Hasegawa, Seiji Ishiguro

    Published 2019-05-01
    Get full text
    Article
  2. 2
    High heat flux reduction to materials using current filaments

    High heat flux reduction to materials using current filaments by Trang Le, Yasuhiro Suzuki, Hiroki Hasegawa, Toseo Moritaka, Hiroaki Ohtani

    Published 2023-05-01
    Get full text
    Article
  3. 3
    Effect of hypoxia on progesterone production by cultured bovine early and mid luteal cells

    Effect of hypoxia on progesterone production by cultured bovine early and mid luteal cells by Hiroki HASEGAWA, Ryo NISHIMURA, Masamichi YAMASHITA, Takeshi YAMAGUCHI, Mitsugu HISHINUMA, Kiyoshi OKUDA

    Published 2018-11-01
    Get full text
    Article
  4. 4
    Al ion-exchanged USY in FCC catalyst for high LPG yield

    Al ion-exchanged USY in FCC catalyst for high LPG yield by Hiroshi Yamazaki, Hiroki Hasegawa, Chisuzu Tanaka, Yusuke Takamiya, Tomohiro Mitsui, Takaki Mizuno

    Published 2021-11-01
    Get full text
    Article
  5. 5
    MicroRNA-205-5p inhibits three-dimensional spheroid proliferation of ErbB2-overexpressing breast epithelial cells through direct targeting of CLCN3

    MicroRNA-205-5p inhibits three-dimensional spheroid proliferation of ErbB2-overexpressing breast epithelial cells through direct targeting of CLCN3 by Takayoshi Takeno, Takuya Hasegawa, Hiroki Hasegawa, Yasuyuki Ueno, Ryo Hamataka, Aya Nakajima, Junji Okubo, Koji Sato, Toshiyuki Sakamaki

    Published 2019-10-01
    Get full text
    Article
  6. 6
    Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

    Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastat... by Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno

    Published 2020-05-01
    Get full text
    Article
  7. 7
    Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

    Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advan... by Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno

    Published 2020-06-01
    Get full text
    Article
  8. 8
    The periodical cicada four-year acceleration hypothesis revisited and the polyphyletic nature of Brood V, including an updated crowd-source enhanced map (Hemiptera: Cicadidae: Magicicada)

    The periodical cicada four-year acceleration hypothesis revisited and the polyphyletic nature of Brood V, including an updated crowd-source enhanced map (Hemiptera: Cicadidae: Magi... by John R. Cooley, Nidia Arguedas, Elias Bonaros, Gerry Bunker, Stephen M. Chiswell, Annette DeGiovine, Marten Edwards, Diane Hassanieh, Diler Haji, John Knox, Gene Kritsky, Carolyn Mills, Dan Mozgai, Roy Troutman, John Zyla, Hiroki Hasegawa, Teiji Sota, Jin Yoshimura, Chris Simon

    Published 2018-07-01
    Get full text
    Article

Search Tools: